Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated bivalent enterovirus 71 and coxsackievirus A16 vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The inactivated bivalent enterovirus 71 and coxsackievirus A16 vaccine is a biologic candidate developed by Sinovac (Beijing Kexing Biological Products) for the prevention of hand, foot, and mouth disease (HFMD) and herpangina. Produced using Vero cell culture technology and subsequently inactivated, the vaccine targets the two most common viral causes of HFMD: Enterovirus 71 (EV71) and Coxsackievirus A16 (CA16). By providing bivalent coverage, it aims to offer broader protection than existing monovalent EV71 vaccines. The vaccine is currently undergoing Phase I/II clinical evaluation in China to assess its safety, tolerability, and immunogenicity across various age groups, including infants as young as 6 months, children, and adults.
- Other names
- bivalent enterovirus vaccine (Vero cell), inactivatedinactivated bivalent EV71 and CA16 vaccinebivalent HFMD vaccine
02
Targets
CA16 (Coxsackievirus A16)Enterovirus A71 capsid proteins VP1, VP2, VP3, and VP4
Beyond the preview
Go deeper on inactivated bivalent enterovirus 71 and coxsackievirus A16 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated bivalent enterovirus 71 and coxsackievirus A16 vaccine.